LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Home・Aktien・Vivani Medical

Vivani Medical

Geschlossen

1.26 0.8

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.21

Max

1.28

Schlüsselkennzahlen
By Trading Economics
Angestellte	37

Dividenden
By Dow Jones
Nächstes Ergebnis	30. März 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-19M 86M
Vorheriger Eröffnungskurs	0.46
Vorheriger Schlusskurs	1.26

Vivani Medical Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Feb. 2026, 23:07 UTC

Ergebnisse

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24. Feb. 2026, 23:01 UTC

Ergebnisse

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24. Feb. 2026, 22:59 UTC

Ergebnisse

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24. Feb. 2026, 22:42 UTC

Ergebnisse

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24. Feb. 2026, 22:24 UTC

Akquisitionen, Fusionen, Übernahmen

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24. Feb. 2026, 23:46 UTC

Market Talk

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24. Feb. 2026, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24. Feb. 2026, 23:30 UTC

Market Talk

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24. Feb. 2026, 23:20 UTC

Market Talk

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24. Feb. 2026, 23:20 UTC

Market Talk

Global Equities Roundup: Market Talk

24. Feb. 2026, 23:16 UTC

Ergebnisse

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24. Feb. 2026, 23:13 UTC

Ergebnisse

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24. Feb. 2026, 23:12 UTC

Ergebnisse

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24. Feb. 2026, 23:10 UTC

Ergebnisse

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24. Feb. 2026, 23:10 UTC

Ergebnisse

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24. Feb. 2026, 23:08 UTC

Ergebnisse

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24. Feb. 2026, 23:07 UTC

Ergebnisse

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24. Feb. 2026, 22:52 UTC

Ergebnisse

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24. Feb. 2026, 22:46 UTC

Ergebnisse

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24. Feb. 2026, 22:31 UTC

Akquisitionen, Fusionen, Übernahmen

Warner Receives New Bid From Paramount -- 3rd Update

24. Feb. 2026, 22:29 UTC

Ergebnisse

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24. Feb. 2026, 22:28 UTC

Ergebnisse

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24. Feb. 2026, 22:27 UTC

Ergebnisse

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24. Feb. 2026, 22:27 UTC

Ergebnisse

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24. Feb. 2026, 22:25 UTC

Ergebnisse

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24. Feb. 2026, 22:24 UTC

Ergebnisse

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24. Feb. 2026, 22:23 UTC

Ergebnisse

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24. Feb. 2026, 22:22 UTC

Ergebnisse

Woolworths Interim Dividend 45 Australian Cents/Share

24. Feb. 2026, 22:22 UTC

Ergebnisse

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24. Feb. 2026, 22:21 UTC

Ergebnisse

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Peer-Vergleich

Kursveränderung

Vivani Medical Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Vivani Medical – Dist abgegeben haben.

Finanzen

Über Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.